Introduction {#s1}
============

Renal cell carcinoma (RCC), one lethal urologic cancer accounting for 2% of all cancer deaths, is the third most common cancer of the genitourinary tract, just next to prostate and bladder cancer [@pone.0081129-Siegel1]. The most common subtype of RCC is the clear cell type (ccRCC), accounting for 75% of all cases. The incidence of RCC has increased rapidly worldwide over the past few decades [@pone.0081129-Chow1]. Although the exact causes of RCC remain unknown, a few well-established lifestyle risk factors have been identified, including: cigarette smoking, obesity, hypertension and diabetes [@pone.0081129-Mathew1]. Recent studies have demonstrated that genetic polymorphisms of candidate genes were associated with susceptibility and/or prognosis of cancers, including RCC [@pone.0081129-Hirata1], [@pone.0081129-Lin1], [@pone.0081129-Kleinrath1], [@pone.0081129-Kawai1].

One-carbon metabolism refers to a system of interdependent metabolic pathways facilitating the transfer of one-carbon units, which are the basement of nucleotide synthesis and the methylation of DNA. Methylation is responsible for gene expression control, chromatin structure stability and the maintenance of genomic stability. It has been proved that tumor-suppressor genes are silenced by hypermethylation of the promoter region in various cancers, leading to carcinogenesis and cancer progression [@pone.0081129-Teodoridis1]. In RCC, genes encoding von Hippel-Lindan (VHL), E-cadherin and RASSF1A have been reported to be inactivated by promoter hypermethylation [@pone.0081129-Shinojima1], [@pone.0081129-Kawakami1], [@pone.0081129-Morrissey1]. DNA hypomethylation begets chromosomal instability as a result of changes in chromatin structure [@pone.0081129-Eden1], [@pone.0081129-Feinberg1].

The connection between the polymorphisms in one-carbon metabolism pathway genes, such as methylenetetrahydrofolate reductase (*MTHFR*), has been widely studied in various cancers [@pone.0081129-Moore1], [@pone.0081129-Gibson1], [@pone.0081129-Flores1], [@pone.0081129-Shen1], [@pone.0081129-Curtin1]. The *MTHFR* promoter polymorphism rs3737965 has been intensively studied, but the results were conflicting, especially in lung cancer [@pone.0081129-Flores1], [@pone.0081129-Cui1], [@pone.0081129-Shi1], [@pone.0081129-Boccia1], [@pone.0081129-Mao1]. Besides, two large case-control studies for RCC have been conducted in Europe to analyze the candidate genes in one-carbon metabolism pathway. The studies found the association between the one-carbon metabolism pathway genes polymorphisms and RCC risk [@pone.0081129-Moore1], [@pone.0081129-Gibson1]. However, there are some discrepancies in these two studies, as evidenced by the confusing connection between the *TYMS* polymorphisms and RCC risk. Given the importance of this pathway in carcinogenesis, ethnic differences and the discrepancies in previous studies, the present case-control study was conducted to define the association between the one-carbon metabolism pathway genes polymorphisms and the ccRCC risk in Chinese population, through testing the polymorphism in six key genes (*CBS, MTHFR, MTR, MTRR, SHMT1*, and *TYMS*) in this pathway.

Materials and Methods {#s2}
=====================

Study Subjects {#s2a}
--------------

859 ccRCC patients and 1005 cancer-free controls were enrolled in our case-control study. All subjects were genetically unrelated ethnic Han Chinese recruited from May 2004 to January 2012 at the First Affiliated Hospital of Nanjing Medical University, Nanjing, China, the Affiliated Hospital of Medical College Qingdao University, Qingdao, China and the Third Affiliated Hospital of Soochow University, Changzhou, China [@pone.0081129-Qin1]. The cases were newly diagnosed with incident ccRCC and had been histopathologically confirmed without history of other malignancies and previous chemotherapy or radiotherapy. A standard questionnaire was administered through face-to-face interviews by trained interviewers to collect demographic data and related information. Each subject donated 5 mL venous blood after signing the agreement. The disease was classified by the World Health Organization criteria and stage according to the American Joint Committee on Cancer (AJCC) TNM (tumor-node-metastasis) classification. The Fuhrman scale was used to assess tumor nuclear grade and the disease stage was divided into two subgroups (localized group: stage I and stage II and advanced group: stage III and stage IV). The controls were individuals without history of cancer who were seeking health care in the outpatient departments matched to the cases\' sex and age (±5 years) on frequency. We subdivided the patients and controls into two groups (younger group: age ≤57 and older group: age \>57) according to the mean age of the cohort (57 years old). Smokers were defined as those who smoked daily for more than 1 year. Drinkers were those who drank at least 3 times per week and more than 6 months. The study was approved by the Institutional Review Board of the Nanjing Medical University, Nanjing, China.

DNA extraction and genotyping {#s2b}
-----------------------------

Genomic DNA was seperated and purified from leucocytes of peripheral blood by proteinase K digestion and phenol/chloroform extraction. Genotyping of the polymorphism was performed by the Snapshot. The SNaPshot SNP assay was performed to detect the dimorphism at the two SNP loci. PCR was performed in a 20 µl reaction mixture containing 1 µl (10 ng) of template DNA, 1 µM of each primer, 0.3 mM of each deoxynucleotide triphosphate, 3.0 mM of MgCl2, and 1 U HotStarTaq polymerase (Qiagen Inc., USA) with 1× HotStarTaq buffer. The PCR program consisted of an initial melting step of 15 minutes at 95°C; 11 cycles of 20 seconds at 94°C, 40 seconds at 65°C-0.5°C/cycle, and 90 seconds at 72°C; 24 cycles of 20 seconds at 94°C, 30 seconds at 59°C, and 90 seconds at 72°C; and a final elongation step of 2 minutes at 72°C. To purify the PCR products, 1 U SAP and 1 U Exonuclease I were mixed with 10 µl PCR product for 1 hour at 37°C and 15 minutes at 75°C.The extension reaction was performed in a 10 µl reaction mixture containing 5 µl of the SNaPshot Multiplex Kit (Applied Biosystems, USA), 2 µl of purified PCR products, 0.8 µM of the extension reaction primer, and 2 µl water. The PCR program was 1 minute at 96°C; 28 cycles of 10 seconds at 96°C, 5 seconds at 50°C, and 30 seconds at 60°C; and 4°C as the holding temperature. Finally, 10 µl of the extension product was purified with 1 U SAP for 1 hour at 37°C and inactivated for 15 minutes at 75°C.The resulting data were analyzed with an ABI3130XL sequencer and GeneMapper™ 4.0 Software (Applied Biosystems, Co. Ltd., USA). All the sequences of primers for each SNP are listed in [Table S1](#pone.0081129.s001){ref-type="supplementary-material"}. Positive controls by sequencing and negative controls were used to ensure the accuracy of genotyping. To ensure quality control (QC), genotyping was performed by researchers blinded to the case/control status of the subjects, and a random sample of 5% of the cases and controls was genotyped twice by different persons, with a reproducibility of 100%.

Statistical analysis {#s2c}
--------------------

Statistical analysis were performed by software SAS 9.1.3 (SAS Institute, Cary, NC). Allele frequencies were tested against departure from Hardy-Weinberg equilibrium through goodness-of-fit χ2 test before analysis. Differences in the distributions of demographic characteristics, selected variables, and frequencies of genotypes between cases and controls were evaluated by Student\'s t-test (for continuous variables) or χ2-test (for categorical variables). OR and 95% CIs from unconditional logistic regression analysis with the adjustment for possible confounders were used to estimate the association between the polymorphism and the risk of ccRCC. All of the statistical tests were two-sided and *P*\<0.05 was considered statistically significant.

Results {#s3}
=======

Characteristics of ccRCC patients and controls {#s3a}
----------------------------------------------

Clinical and pathologic characteristics of the 859 cases and 1005 controls are presented in [Table 1](#pone-0081129-t001){ref-type="table"} (negative results listed in [Table S2](#pone.0081129.s002){ref-type="supplementary-material"}). No significant differences were found between the cases and controls in regards to age, gender and drinking status (all *P*\>0.05). However, there were more high BMI, smoking habit, hypertension and diabetes subjects in ccRCC patients than those in controls (*P* = 0.003, *P* = 0.040, *P*\<0.001 and *P* = 0.040, respectively). Among 859 ccRCC cases, 577 (67.2%) patients were diagnosed with stage I disease, 170 (19.8%) patients with stage II, 57 (6.7%) patients with stage III, and 55 (6.4%) patients with stage IV. The percent of nuclear grade from I to IV was 20.5%, 54.7%, 19.9%, and 4.9%, respectively.

10.1371/journal.pone.0081129.t001

###### Distribution of selected variables between the clear cell renal cell carcinoma cases and control subjects.

![](pone.0081129.t001){#pone-0081129-t001-1}

  Variables                  Cases (n = 859)   Controls (n = 1005)   *P*-value[a](#nt101){ref-type="table-fn"}         
  ------------------------- ----------------- --------------------- ------------------------------------------- ------ -------------
  Age (years) (mean ± SD)       57.0±11.7           57.2±12.4                          0.758                           
  BMI (kg/m2) (mean ± SD)       24.2±2.9            23.8±3.2                         **0.003**                         
  Gender                                                                                                               
  Male                             557                64.8                              688                      68.5      0.098
  Female                           302                35.2                              317                      31.5  
  Smoking status                                                                                                       
  Never                            530                61.7                              666                      66.3    **0.040**
  Ever                             329                38.3                              339                      33.7  
  Drinking status                                                                                                      
  Never                            619                72.1                              757                      75.3      0.110
  Ever                             240                27.9                              248                      24.7  
  Hypertension                                                                                                         
  No                               522                60.8                              675                      67.2   **\<0.001**
  Yes                              337                39.2                              251                      25.0  
  Diabetes                                                                                                             
  No                               748                87.6                              870                      86.6   **\<0.001**
  Yes                              111                12.4                              56                       5.6   
  Clinical stage                                                                                                       
  I                                577                67.2                                                             
  II                               170                19.8                                                             
  III                              57                  6.7                                                             
  IV                               55                  6.4                                                             
  Grade                                                                                                                
  I                                176                20.5                                                             
  II                               470                54.7                                                             
  III                              171                19.9                                                             
  IV                               42                  4.9                                                             

Student\'s t-test for age and BMI distributions between cases and controls; two-sided χ2-test for others selected variables between cases and controls.

Association of SNPs with the risk of ccRCC {#s3b}
------------------------------------------

As shown in [Table 2](#pone-0081129-t002){ref-type="table"}, except the rs1788484 in *CBS* gene and rs10520873 in *MTRR* gene, the genotype distributions of all other SNPs were in agreement with Hardy-Weinberg equilibrium in controls. Therefore, the rs1788484 and rs10520873 were excluded for further analysis. [Table 2](#pone-0081129-t002){ref-type="table"} shows ccRCC risks were associated with each single polymorphism. We presented each of the associations in additive, dominative and recessive models. In *CBS* gene, the genotype of rs706209 polymorphism distribution between cases and controls was significantly different (*P* = 0.006). In the dominant model, when compared with the homozygous wild-type reference group, TC+CC genotype was significantly associated with a decreased risk of ccRCC (*P* = 0.002, adjusted OR = 0.76, 95%CI = 0.62--0.91). In *MTRR* gene, the genotype of rs9332 polymorphism distribution between cases and controls was significantly different (*P* = 0.027). In the dominant model, CT+TT genotype was significantly associated with a decreased risk of ccRCC (*P* = 0.010, adjusted OR = 0.74, 95%CI = 0.60--0.92), when compared with the CC group. The rs2966952 seemed to be a bordering positive result. In the recessive models, TT genotype was slightly associated with an increased risk of ccRCC (*P* = 0.050, adjusted OR = 1.34, 95%CI = 1.00--1.80), compared with the CC+CT genotype. In *TYMS* gene, the genotype of rs2853741 polymorphism distribution between cases and controls had no significantly difference (*P* = 0.096). In the dominant model, TC+CC genotype was significantly associated with an increased risk of ccRCC (*P* = 0.032, adjusted OR = 1.25, 95%CI = 1.02--1.53), when compared with the TT group. Similarly, for the rs699517, the polymorphism distribution between cases and controls had no significantly difference (*P* = 0.108). In the recessive models, CC genotype was seemed to be associated with an increased risk of ccRCC (*P* = 0.172, adjusted OR = 1.25, 95%CI = 1.03--1.51).

10.1371/journal.pone.0081129.t002

###### Polymorphism in one-carbon metabolism genes and clear cell renal cell carcinoma risk.
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                  Position    MAF    Cases, n (%)   Controls, n (%)   *P*-value[a](#nt102){ref-type="table-fn"}   Adjusted OR (95% CI)[b](#nt103){ref-type="table-fn"}   *P* trend[a](#nt102){ref-type="table-fn"}       HWE
  -------------- ---------- ------- -------------- ----------------- ------------------------------------------- ------------------------------------------------------ ------------------------------------------- -------------
  *CBS*                                                                                                                                                                                                             
  rs1788484       promoter   0.222                                                                                                                                                                                  
  CC                                  535(62.3)        543(54.0)                     **\<0.001**                                          Ref.                                           **0.022**                   **\<0.001**
  CT                                  275(32.0)        425(42.3)                                                                    0.62(0.51--0.76)                                                                
  TT                                   49(5.7)          37(3.7)                                                                     1.27(0.79--2.20)                                                                
  TT vs. CC+CT                                                                        **0.038**                                     1.53(0.97--2.41)                                                                
  CT+TT vs. CC                                                                       **\<0.001**                                  **0.67(0.55--0.82)**                                                              
  rs706209         3′UTR     0.329                                                                                                                                                                                  
  TT                                  401(46.7)        396(39.4)                      **0.006**                                           Ref.                                           **0.007**                      0.379
  TC                                  358(41.7)        480(47.8)                                                                  **0.76(0.62--0.92)**                                                              
  CC                                  100(11.6)        129(12.8)                                                                    0.74(0.55--1.01)                                                                
  CC vs. TT+TC                                                                          0.434                                       0.87(0.65--1.16)                                                                
  TC+CC vs. TT                                                                        **0.002**                                   **0.76(0.62--0.91)**                                                              
  *MTRR*                                                                                                                                                                                                            
  rs2966952       promoter   0.333                                                                                                                                                                                  
  CC                                  371(43.2)        463(46.1)                        0.120                                             Ref.                                             0.064                        0.978
  CT                                  374(43.5)        438(43.6)                                                                    1.07(0.88--1.31)                                                                
  TT                                  114(13.3)        104(10.4)                                                                  **1.40(1.03--1.91)**                                                              
  TT vs. CC+CT                                                                        **0.050**                                   **1.34(1.00--1.80)**                                                              
  CT+TT vs. CC                                                                          0.213                                       1.13(0.93--1.36)                                                                
  rs9332           3′UTR     0.188                                                                                                                                                                                  
  CC                                  651(75.8)        708(70.5)                      **0.027**                                           Ref.                                           **0.007**                      0.434
  CT                                  196(22.8)        275(27.4)                                                                  **0.75(0.60--0.93)**                                                              
  TT                                   12(1.4)          22(2.2)                                                                     0.65(0.31--1.33)                                                                
  TT vs. CC+CT                                                                          0.203                                       0.70(0.34--1.43)                                                                
  CT+TT vs. CC                                                                        **0.010**                                   **0.74(0.60--0.92)**                                                              
  rs10520873       3′UTR     0.311                                                                                                                                                                                  
  AA                                  593(69.0)        648(64.5)                        0.063                                             Ref.                                             0.098                      **0.032**
  AG                                  240(27.9)        331(32.9)                                                                  **0.79(0.64--0.97)**                                                              
  GG                                   26(3.0)          26(2.6)                                                                     1.15(0.65--2.04)                                                                
  GG vs. AA+AG                                                                          0.566                                       1.24(0.70--2.19)                                                                
  AG+GG vs. AA                                                                        **0.038**                                   **0.82(0.67--1.00)**                                                              
  *TYMS*                                                                                                                                                                                                            
  rs2853741       promoter   0.411                                                                                                                                                                                  
  TT                                  264(30.7)        356(35.4)                        0.096                                             Ref.                                           **0.046**                      0.982
  TC                                  439(51.1)        484(48.2)                                                                  **1.25(1.01--1.54)**                                                              
  CC                                  156(18.2)        165(16.4)                                                                    1.24(0.93--1.64)                                                                
  CC vs. TT+TC                                                                          0.321                                       1.08(0.84--1.39)                                                                
  TC+CC vs. TT                                                                        **0.032**                                   **1.25(1.02--1.53)**                                                              
  rs699517         3′UTR      0.3                                                                                                                                                                                   
  TT                                  420(48.9)        537(53.4)                        0.108                                             Ref.                                                                      
  TC                                  358(41.7)        391(38.9)                                                                  **1.25(1.02--1.52)**                                   **0.035**                      0.619
  CC                                   81(9.4)          77(7.7)                                                                     1.26(0.89--1.78)                                                                
  CC vs. TT+TC                                                                          0.172                                     **1.25(1.03--1.51)**                                                              
  TC+CC vs. TT                                                                          0.051                                       1.15(0.82--1.61)                                                                

Two-sided χ2-test for either genotype distributions or trend between the cases and controls.

genotype-specific ORs were adjusted for age, gender, BMI, smoking status, drinking status, diabetes and hypertension in logistic regression model.

Combined Analysis of Polymorphisms {#s3c}
----------------------------------

Rs706209 or rs9332 alone being associated with ccRCC risk, we combined these two polymorphisms based on the number of the variant alleles. As shown in [Table 3](#pone-0081129-t003){ref-type="table"}, statistically significant difference was obviously found between the subgroups and the risk of ccRCC. Meanwhile, individuals carrying 1, 2, 3, or 4 variant alleles in these two genes were associated with a statistically significantly decreased risk of ccRCC compared with individuals carrying none variant alleles (*P* = 0.001, adjusted OR = 0.73, 95%CI = 0.06--0.90).

10.1371/journal.pone.0081129.t003

###### Combined genotype frequencies among the case patients and control subjects and their collection to clear cell renal cell carcinoma.
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  Variables                Case (n = 859)   Controls (n = 1005)   *P*-value[a](#nt104){ref-type="table-fn"}   Adjusted OR (95% CI)[b](#nt105){ref-type="table-fn"}              
  ----------------------- ---------------- --------------------- ------------------------------------------- ------------------------------------------------------ ----------- ----------------------
  rs706209 and rs9332                                                                                                                                                           
  Number of risk allele                                                                                                                                                         
   0                            304                35.4                              286                                              28.5                                      
   1                            358                41.7                              432                                              43.0                           **0.022**   **0.79(0.64--0.99)**
   2                            171                19.9                              237                                              23.6                           **0.003**   **0.68(0.52--0.88)**
   3                             26                 3.0                              49                                               4.9                            **0.006**   **0.48(0.29--0.81)**
   4                             0                   0                                1                                                0                                        
  Recombined groups                                                                                                                                                             
   0                            304                35.4                              286                                              28.5                                      
   1--4                         555                64.6                              719                                              71.5                           **0.001**   **0.73(0.06--0.90)**

Two-sided χ2 test for the distributions of genotypes.

Adjusted for age, gender, BMI, smoking status, drinking status, hypertension and diabetes in logistic regression model.

Stratified Analysis of the Two Polymorphisms and Clinicopathologic Characteristics and Risk of ccRCC {#s3d}
----------------------------------------------------------------------------------------------------

We further evaluated the association between the combined genotypes of rs706209 and rs9332 polymorphisms and clinicopathologic characteristics of ccRCC. These two polymorphisms were combined based on the number of the variant alleles. As shown in [Table 4](#pone-0081129-t004){ref-type="table"}, a significantly increased risk appeared in ccRCC patients with localized stage (*P* = 0.002, adjusted OR = 1.37, 95%CI = 1.11--1.69) and in patients with well-differentiated ccRCC (*P*\<0.001, adjusted OR = 1.42, 95%CI = 1.14--1.76).

10.1371/journal.pone.0081129.t004

###### Association between the combined genotypes of rs706209 and rs9332 polymorphisms and clinicopathologic characteristics of clear cell renal cell carcinoma.
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  Variables                                       Risk allele   *P*-value[a](#nt106){ref-type="table-fn"}   Adjusted OR (95% CI)[b](#nt107){ref-type="table-fn"}  
  ---------------------------------------------- ------------- ------------------------------------------- ------------------------------------------------------ -----------------------
  Control (n = 1005)                               286(28.5)                    719(71.5)                                                                                  Ref.
  Case (n = 859)                                                                                                                                                  
  Clinical stage                                                                                                                                                  
  Localized (I+II)                                 265(35.5)                   482 (64.5)                                        **0.002**                         **1.37 (1.11--1.69)**
  Advanced (III+IV)                                39 (34.8)                    73 (65.2)                                          0.160                             1.30 (0.86--1.98)
  Grade                                                                                                                                                           
  Well- differentiated (I+II)                     234 (36.2)                   412 (63.8)                                       **\<0.001**                        **1.42 (1.14--1.76)**
  Moderately and Poorly differentiated(III+IV)     70 (32.9)                   143 (67.1)                                          0.199                             1.21 (0.87--1.68)

Two-sided χ2 test for the distributions of genotypes.

Adjusted for age, gender, BMI, smoking status, drinking status, hypertension and diabetes in logistic regression model.

As shown in [Table 5](#pone-0081129-t005){ref-type="table"}, the analysis was stratified by age, gender, smoking status, and drinking status. Individuals carrying none variant allele in older group (*P* = 0.007, adjusted OR = 0.67, 95%CI = 0.49--0.91), male group (*P* = 0.007, adjusted OR = 0.71, 95%CI = 0.55--0.92), never smoking group (*P* = 0.002, adjusted OR = 0.68, 95%CI = 0.53--0.88) and never drinking group (*P*\<0.001, adjusted OR = 0.68, 95%CI = 0.53--0.88) had an increased ccRCC risk.

10.1371/journal.pone.0081129.t005

###### Association between the combined genotypes of rs706209 and rs9332 polymorphisms and clear cell renal cell carcinoma in stratified analysis.
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  Variables    Risk allele   *P*-value[a](#nt108){ref-type="table-fn"}   Adjusted OR (95% CI)[b](#nt109){ref-type="table-fn"}                            
  ----------- ------------- ------------------------------------------- ------------------------------------------------------ ----------- ------------- ----------------------
  Age                                                                                                                                                    
  \< = 57       161(36.2)                    164(30.4)                                        284(63.8)                         376(69.6)      0.054        0.78(0.60--1.02)
  \>57          143(34.5)                    122(26.2)                                        271(65.5)                         343(73.8)    **0.007**    **0.67(0.49--0.91)**
  Gender                                                                                                                                                 
  Male          192(34.5)                    188(27.3)                                        365(65.5)                         500(72.7)    **0.007**    **0.71(0.55--0.92)**
  Female        121(37.1)                    98(30.9)                                         190(62.9)                         219(69.1)      0.105        0.77(0.55--1.08)
  Smoke                                                                                                                                                  
  Never         193(36.4)                    187(28.1)                                        337(63.6)                         479(71.9)    **0.002**    **0.68(0.53--0.88)**
  Ever          111(33.7)                    99(29.2)                                         218(66.3)                         240(70.8)      0.207        0.83(0.59--1.17)
  Drink                                                                                                                                                  
  Never         229(37.0)                    202(26.7)                                        390(63.0)                         555(73.3)   **\<0.001**   **0.68(0.53--0.88)**
  Ever          75(31.3)                     84(33.9)                                         165(68.8)                         164(66.1)      0.537        0.83(0.59--1.17)

Two-sided χ2 test for the distributions of genotypes.

Adjusted for age, gender, BMI, smoking status, drinking status, hypertension and diabetes in logistic regression model.

Discussion {#s4}
==========

Our study supports a role that *CBS*, *MTRR*, and *TYMS* play in modifying ccRCC risk. Meanwhile, we also notice the discrepancies between our findings and the results reported by the two European studies. Moore *et al.* reported that *MTHFR* and *TYMS* had effect on RCC risk, while *CBS*, *MTR*, or *MTRR* had no [@pone.0081129-Moore1]. Gibson *et al.* reported that the strongest association between RCC risk and *MTHFR*, not *CBS*, *MTR*, *MTRR*, *SHMT1* or *TYMS*, was observed [@pone.0081129-Gibson1]. The discrepancies might be due to the different aspect of study, different ethnic population and other unknown factors. Our current study is focus on the ccRCC, which is one part of RCC.The pathologic characteristics of ccRCC in our study may be relatively simple, when compared with these two European articals. In the dbSNP database, the minor allele frequency (MAF) of rs706209 was T allele  = 0.403 in European, but the MAF in Chinese was C allele  = 0.402, close to our data C allele  = 0.482. As involved in one-carbon metabolism pathway, the *CBS* gene encodes cystathionine beta synthase (CBS), which is the central enzyme in the transsulfuration pathway irreversibly metabolizing homocysteine (Hcy) to cystathionine [@pone.0081129-Yi1]. Evidences showed that functional *CBS* gene SNP could impair *CBS* gene function, leading to an increase in the concentration on tHcy that further influenced aberrant DNA methylation patterns and *CBS* gene SNP had associations with lung cancer, colorectal cancer and head and neck squamous cell carcinoma [@pone.0081129-Flores1], [@pone.0081129-LeMarchand1], [@pone.0081129-Galbiatti1]. Whether rs706209 has the similar influence on the *CBS* gene function needs further functional studies. MTRR catalyzes reductive methylation of cob (II)alamin by using SAM as a methyl donor to reactivate MTR. Thus, MTRR may act as a key regulator of the homocysteine conversion to methionine [@pone.0081129-Leclerc1]. Our study demonstrated that CT+TT genotype of rs9332 was significantly associated to a decreased risk of ccRCC. Other report demonstrated that rs9332 in *MTRR* had connections with spina bifida and conotruncal heart defects [@pone.0081129-Shaw1]. Although little information about the function of this polymorphism was known, it is known that 3′UTR of the *MTRR* gene may influence miRNA or siRNA binding target site, causing the degradation of the mRNA, or inhibiting translation initiation. This polymorphism has a protective role in the risk of ccRCC. More researches should be done to reveal the relationship between them.

Moreover, we found that *TYMS* SNPs (rs2966952 and rs699517) had some of connections with ccRCC risk. Skibola *et al.* reported that C allele in rs699517 was approximately 100% correlated with *TYMS* 1496 insertion and T allele in rs699517 was also approximately 100% correlated with *TYMS* 1496 deletion. The *TYMS* 1496 deletion polymorphism was associated with decreased mRNA stability and low expression in tumor tissue than the wild type polymorphism [@pone.0081129-Skibola1], [@pone.0081129-Mandola1], [@pone.0081129-Ulrich1]. Evidence demonstrated that the level of thymidylate synthetase (TS) activity was correlated with both the progression of the stage and the increase of the grade of RCC, and the activity of TS was approximately 5-fold higher in RCC compared with normal kidney [@pone.0081129-Mizutani1].

There were several limitations in our present study. Firstly, our standard questionnaire contained no environmental factors, such as occupational exposure, and personal habits, such as diet and physical activity. So our study may have a limited statistical power, such as that we could not do further analysis in gene-environment interaction. Secondly, more and more studies indicated that gene-gene interaction may also have contribution to the risk of cancer [@pone.0081129-Zhong1], [@pone.0081129-Liu1]. In the current study, we did little analysis about the interaction among genes in the one-carbon metabolism pathway. So the results may exist some interaction bias. Furthermore, our study was designed as a hospital-based study, so the possibility of selection bias of subjects could not be ruled out. Thirdly, the genotype distributions of rs1788484 in *CBS* gene and rs10520873 in *MTRR* gene were departed from Hardy-Weinberg equilibrium in controls. The probability of genotyping error was very low. Meanwhile, Galbiatti *et al.* also reported that polymorphism of *CBS* gene was not in Hardy-Weinberg equilibrium [@pone.0081129-Galbiatti1]. The departure from the Hardy-Weinberg equilibrium may result from selection bias, disease model adopted, and evolutionary factors which may influence changes in the genotype frequencies [@pone.0081129-Xu1], [@pone.0081129-Llorca1]. On the other hand, this disequilibrium should be expected, in the case that it reflected biological and genetic characteristics in complex disease models [@pone.0081129-WittkeThompson1].

In summary, the data indicates that the common variation in *CBS*, *MTRR* and *TYMS* may significantly modify ccRCC risk.
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